Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2006 April;54(2) > Minerva Cardioangiologica 2006 April;54(2):215-27





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752




Minerva Cardioangiologica 2006 April;54(2):215-27

language: English

Dyslipidemia in the metabolic syndrome: clinical implications and management

Hafidh S. A. S., Lavie C. J., Burns B. P., Khan S. S., Alpert M. A.

Department of Medicine St. John’s Mercy Medical Center, St. Louis, MO, USA Department of Cardiovascular Diseases Ochsner Clinic Foundation, New Orleans, LA, USA


Dyslipidemia is an important component of the metabolic syndrome. Dyslipidemia in the metabolic syndrome is characterized by hypertriglyceridemia, low serum levels of high density lipoprotein cholesterol (HDL-C) and an increase in the serum fraction of small dense low density lipoprotein cholesterol (LDL-C) particles. Serum LDL-C elevation is frequently present, but is not a criterion of the metabolic syndrome. A Medline search was conducted using the terms metabolic syndrome, dyslipidemia, hypertriglyceridemia and HDL cholesterol. The metabolic syndrome is a common and important risk factor for cardiovascular disease and progression to type 2 diabetes mellitus. Dyslipidemia is present in most patients with the metabolic syndrome and is treatable with therapeutic lifestyle changes and pharmacotherapy. Aggressive management of atherogenic dyslipidemia is justified by the very high cardiovascular risk associated with this disorder. Atherogenic dyslipidemia is frequently present in patients with the metabolic syndrome and requires aggressive treatment due to the very high risk for cardiovascular disease and progression to type 2 diabetes mellitus.

top of page

Publication History

Cite this article as

Corresponding author e-mail